Main Menu
Documents
Follow us...
Login Form
Welcome to the website of Lipopharma, a pioneering clinical-stage biopharmaceutical company that focuses on the discovery, design and clinical development of a new generation of medicines that act through the innovative therapeutic strategy known as “Membrane-Lipid Therapy” (MLT).
Lipopharma arose in 2006 with the objective to develop breakthrough inventions patented by the University of the Balearic Islands (UIB) in Mallorca, Spain.
Latest News
Lipopharma awarded a 6,15M€ grant by the H2020 Programme to conduct a PIIb trial with 2OHOA in patients with newly-diagnosed glioblastoma
The European Commission (EC) has awarded a 6,15M€ grant to develop the project CLINGLIO to a multinational consortium lead by Lipopharma and integrated by 12 leading clinical research institutions, Universities and SMEs from Europe, Israel and the USA. The objective of CLINGLIO is the execution of “A Clinical Phase IIB trial with 2OHOA in patients with newly-diagnosed malignant glioma”. The duration of the CLINGLIO project is 36 months and the starting date is 1st of December, 2017
Palma de Mallorca (Spain) and Acton (MA, USA). January 21st 2018.– Lipopharma, a pioneering clinical stage biopharmaceutical company developing a new generation of products modulating metabolism of membrane lipids based on the groundbreaking MLT platform, announces that the European Commission has awarded a 6,15M€ grant to the CLINGLIO consortium, lead by Lipopharma, to execute the project entitled “A Clinical Phase IIB trial with 2OHOA in patients with newly-diagnosed malignant glioma”.
Final results of the MIN-001-1203 study with 2OHOA in oncology presented at ASCO 2017 annual meeting in Chicago
54 patients with advanced solid tumours have participated in the Phase I/IIa clinical study with 2OHOA, half of them with malignant glioma. Primary objective has been achieved, with the definition or the MTD, the confirmation of an excellent safety profile, even at doses well above the expected therapeutic range and the identification of the recommended Phase 2 dose (RP2D). A favourable PK profile, with no food‑effect interactions and supporting oral dosing of 2OHOA was also determined. Very encouraging clinical activity has been observed in at least 8 patients with recurrent solid tumours, five of them with malignant glioma. Preliminary biomarkers analysis confirm biological activity of 2OHOA in patients and several potential plasmatic biomarkers have already been identified for future development and validation.
2OHOA, a new hope
CLINGLIO
